| Project/Area Number |
17K15946
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Shiraha Hidenori
Sawahara Hiroaki
Ohyama Atsushi
Tanaka Emi
|
|---|
| Project Period (FY) |
2017-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 遺伝子治療 / REIC/Dkk-3遺伝子 / 胆道癌 / 膵癌 / REIC遺伝子 / 抗癌剤耐性 / REIC/DKK3 / 胆膵癌 |
|---|
| Outline of Final Research Achievements |
REIC/Dkk-3 gene expression was decreased in various cancer cells, and overexpression of REIC/Dkk-3 gene induces cancer cell death. This novel gene therapy for prostate cancer, malignant mesothelioma, and hepatocellular carcinoma was previously reported, and clinical studies have already started. We evaluated the efficacy of this gene therapy for pancreaticobiliary cancer including drug-resistant cancer cells. Our study proved the efficacy of REIC/Dkk-3 gene therapy using adenoviral vector for pancreaticobiliary cancer cell including drug-resistant cells.
|
| Academic Significance and Societal Importance of the Research Achievements |
膵癌、胆道癌および抗癌剤耐性をもった癌に対する新たな治療法として、REIC遺伝子治療が有用である可能性を示した。すでに泌尿器癌、悪性中皮腫、肝癌に対する臨床試験が進行中であり、本研究の成果をもとにさらに対象とする癌腫が拡大されることが期待される。難治癌として知られる膵癌、胆道癌における新規治療法として期待され、その学術的意義、社会的意義は大きいと考える。
|
